Tag: BAVENCIO
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Featured Article
A business-led approach to maximising your SAP investment
Manufacturers are responding to the low-growth environment by focusing on digitisation, ESG and portfolio reshaping, transforming into more digital, resilient, and sustainable organisations.
